anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Due to the ban on the use of traditional brominated flame retardants, new brominated flame retardants, such as Bis (2-ethylhexyl)-2,3,4,5-tetrabromophthalate (TBPH), have been developed as alternatives to traditional brominated flame retardants to replace the old ones, and TBPH has been widely used. Therefore, we need to systematically evaluate the toxicological effects of TBPH. In the current work, we analyzed the effects of TBPH on lung. In vivo model, we found that TBPH treatment caused damage to lung tissues through H&E staining, immunohistochemistry, and western-blot analysis. Furthermore, in vitro model, our study found that TBPH treatment led to a decrease in the proliferative capacity of lung cells. Furthermore, TBPH treatment led to inflammatory responses and oxidative stress in lung cells. Molecular mechanism studies showed that under exposure to TBPH, the biological function of mitochondria was disrupted, leading to the release of endogenous ds-DNA from mitochondria into the cytosol. This released ds-DNA acts as a danger signal molecule, effectively activating the cGAS-STING signaling pathway and subsequent inflammatory responses. Further research showed that the disruption of mitochondrial homeostasis by TBPH is closely related to lung injury. The current research findings not only enrich our understanding of the potential toxicological effects of new brominated flame retardants as environmental pollutants, but also provide a research foundation for further understanding TBPH toxicology.
PROBLEM TO BE SOLVED: To support symptom input by specifying the symptom of an experimental animal on the basis of image data.SOLUTION: An experimental animal 16 in a cage 15 is photographed by video cameras 11 and 12 so that moving image data can be obtained. The moving image data are stored in an image storage part 21. The activity of an experimental animal is quantized from different points of view on the basis of the moving image data by an activity data calculation part 22 so that a plurality of different activity data can be calculated. A multi-dimensional, for example, two-dimensional vector space is configured of the plurality of different activity data by a symptom specification part 23. The activity data are mapped in the two-dimensional vector space. A partial space where the same symptoms mutually gather obtained from the mapped points is defined as a specific symptom partial space. The symptoms added to the specific symptom partial space are determined as symptom candidates with respect to the vector of the activity data belonging to the specific symptom partial space. The symptom candidates are displayed on a symptom input picture as input candidates, and the input of the symptoms is accepted.
Participants (\>= 6 months and \<= 24 months of age) will receive JNJ-53718678 oral solution or placebo \[either in a qd or a bid regimen\] on Day 1 to Day 7. The cohort 1e is optional and may be included at the discretion of the sponsor.
PURPOSE:To enable sterilization of lactoferrin in a state of maintained physiological functionality thereof without forming precipitates by regulating the ionic strength of an aqueous solution of the lactoferrin within a specific range. CONSTITUTION:An aqueous solution of lactoferrin is thermally sterilized. In the process, the ionic strength of the aqueous solution is regulated under conditions expressed by the formula (T is temperature  deg.C) and then sterilized. The lactoferrin is an iron-binding milk protein and has various physiological activities, such as bacteriostatic action on pathogenic bacteria, differentiation regulating action on leukocytes, sterilizing power enhancing action, propagating action on lymphocytes and iron absorption regulating action, and is utilizable also as food materials. The concentration of the aqueous solution of lactoferrin may be high. In this case, the solution is desalted to provide an ionic strength (I) corresponding to the conditions expressed by the formula and regulated.
The overall goal of this research program is to provide effective culturally relevant care to Latin families, and address the National Institute on Minority Health and Health Disparities (NIMHD) mission of reducing disparities in underserved and minority populations. Evidence-based and culturally centered treatments for Latinx teens (Latinx = gender inclusive term) with suicidal ideation and attempts (SIA) and their families are quite limited. Emerging evidence indicate that Cognitive behavioral therapy (CBT) is a promising treatment approach in reducing suicidal ideation and attempts in Non-Latinx White adolescents. However, culturally adapted treatments have been shown to benefit Latin families more that non-culturally adapted treatments. This study is innovative in its use of a culturally centered CBT treatment protocol (Socio-Cognitive Behavioral Therapy for Suicidal Behavior-SCBT-SB) to address the specific needs of Latinx teens and their families. The SCBT-SB, is a modified version of two CBT protocols, which addresses central issues in adolescent identity formation (e.g. ethnicity, sexual orientation), family interactions and communication, and parenting skills. The SCBT-SB was developed with Latinx youth with SIA in Puerto Rico and further modified for Latin families in the US. Feasibility of this modified version of the SCBT-SB was tested in the US by conducting a pilot randomized clinical trial (RCT) (n=46) of SCBT vs treatment-as-usual (TAU) with positive results. It was found that SCBT-SB was feasible to implement in a community mental health center with frontline therapists, acceptable to families, and showed reductions in suicidal ideation and depressive symptoms. The scientific premise of the proposed study is that immigration and acculturation (the process of assimilation to the host culture) and enculturation (maintaining cultural values and costumes) experiences have an impact on SIA in Latinx teens; and that personalization of an evidence-based treatment, according to cultural and immigration experiences, will result in better treatment outcomes than TAU. This application proposes a hybrid efficacy/effectiveness trial with 160 suicidal Latinx teens randomly assigned, following baseline assessment, to 2 treatment conditions, TAU and SCBT-SB. Follow-up assessment will take place at 3, 6 and 12 months after baseline. All treatment will take place at a community mental health clinic. The specific aims are: 1) To test the effect of the SCBT-SB versus TAU on suicidal ideation in a clinical sample of adolescents under conditions of strong external validity, and 2) To test the effect of the SCBT-SB versus TAU on depressive symptoms, given its high correlation with SIA. Exploratory aims are: 3) To examine the effect of SCBT-SB versus TAU on suicide attempts, and 4) To examine potential mediators (family environment) of treatment outcome. Successful completion of this study will positively impact treatment of Latinx immigrant adolescents at high risk of SIA in the US.
The present invention concerns methods and compositions for in vivo and in vitro targeting. A large number of targeting peptides directed towards human organs, tissues or cell types are disclosed. The peptides are of use for targeted delivery of therapeutic agents, including but not limited to gene therapy vectors. A  novel class of gene therapy vectors is disclosed. Certain of the disclosed peptides have therapeutic use for inhibiting angiogenesis, inhibiting tumor growth, inducing apoptosis, inhibiting pregnancy or inducing weight loss. Methods of identifying novel targeting peptides in humans, as well as identifying endogenous receptor-ligand pairs are disclosed. Methods of identifying novel infectious agents that are causal for human disease states are also disclosed. A novel mechanism for inducing apoptosis is further disclosed.
OBJECTIVES: Previous observational epidemiological studies have identified a potential association between inflammatory bowel disease (IBD) and sarcoidosis. Nonetheless, the precise biological mechanisms underlying this association remain unclear. Therefore, we adopted a Mendelian randomization (MR) approach to investigate the causal relationship between IBD with genetic susceptibility to sarcoidosis, as well as to explore the potential mediating role.
METHODS: The genetic associations were obtained from publicly available genome-wide association studies (GWASs) of European ancestry. The IBD dataset has 31,665 cases and 33,977 controls, consisting of 13,768 individuals with ulcerative colitis (UC) and 17,897 individuals with Crohn's disease (CD). The genetic associations of sarcoidosis with 4,854 cases and 446,523 controls. A bidirectional causality between IBD and sarcoidosis was implemented to be determined by a two-sample MR approach. The inverse variance weighted (IVW) method was utilized as the main statistical method, and a series of sensitivity analyses were performed to detect heterogeneity and horizontal pleiotropy. A two-step MR approach was used to investigate whether the mediating pathway from IBD to sarcoidosis was mediated by PBC.
RESULTS: The forward MR analysis indicated that genetic predisposition to IBD was significantly linked to an increased risk of sarcoidosis (OR = 1.088, 95% CI: 1.023-1.158, pIBD-sar = 7.498e-03). Similar causal associations were observed in CD (OR = 1.082, 95% CI: 1.028-1.138, pCD-sar = 2.397e-03) and UC (OR = 1.079, 95% CI: 1.006-1.158, pUC-sar = 0.034). Reverse MR analysis revealed that genetic susceptibility to sarcoidosis was correlated with an augmented risk of CD (OR = 1.306, 95% CI: 1.110-1.537, psar-CD = 1.290e-03) but not IBD or UC. The mediation analysis via two-step MR showed that the causal influence of IBD and CD on sarcoidosis effects was partly mediated by PBC, and the mediating effect was 0.018 (95% CI: 0.005-0.031, p = 7.596e-03) with a mediated proportion of 21.397% in IBD, and 0.014 (95% CI: 0.004-0.024, p = 7.800e-03) with a mediated proportion of 17.737% in CD.
CONCLUSIONS: The MR analysis provided evidence substantiating the causal effect of IBD (CD and UC) on an increased risk of sarcoidosis, with PBC playing a mediating role in IBD and CD. However, sarcoidosis only enhances the risk of developing CD, but not IBD or UC. These findings illuminate the etiology of sarcoidosis and contribute to the management of IBD patients.
A food supplement comprises creatine suspended in an edible supporting matrix. The supporting matrix is preferably a concentrated Aloe Vera gel with an acidic pH, it may also comprise other spreadable solids such as honey, syrup, molasses or treacle. Alternatively the supporting matrix could be a gum, polysaccharide or gelatinous substance. The supplement may contain electrolytes, vitamins, lipids, carbohydrates, amino acids, trace elements, colourings, flavours, artificial sweeteners, antioxidants, stabilizers, preservatives and buffers. The creatine may be in the form of creatine monohydrate or creatine phosphate, and is preferably stable at room temperature for at least 7 days. Methods of preparing and of storing creatine in the supplement form are disclosed, which inhibit conversion to creatinine at room temperature and at acidic pH.
A polyethylene glycol-modified angiogenesis inhibitor HM-1 and its application are disclosed. The polypeptide sequence is mPEG-Arg-Gly-Ala-Asp-Arg-Ala-Gly-Gly-Gly-Gly-Arg-Gly-Asp (SEQ ID NO: 1), and mPEG . . . is chosen from mPEG-SC, mPEG2-NHS, mPEG-ALD or mPEG-bALD, with a molecular weight range of 500˜40000. The polypeptide has been modified by polyethylene glycol, has the capacity to inhibit vascular endothelial cell migration and integrin affinity and binding, and can be used for the prevention and treatment of tumors, various types of inflammation, and neovascular eye diseases. The polyethylene glycol-modified angiogenesis inhibitor disclosed by the present invention is prepared by a synthetic method.
Nanoliposomal irinotecan 70 mg/ IV over 90 minutes, every 14 days. Leucovorin 400 mg/ IV over 30 minutes, every 14 days. Fluorouracil 2,400 mg/m IV over 46 hours.
Subjects will receive standard of care treatment. ODSH is administered in bolus doses estimated to inhibit inflammatory mediators randomized 1:1 to ODSH 8mg/kg or placebo. The continuous infusion dose will be 0.375 mg/kg/hr over 96 hours.
The dose of PRAME-TCR-NK cells you receive will depend on when you join this study. Up to 5 dose levels of the study product will be tested. The first group of participants will receive the lowest dose level of the study product. Each new group will receive a higher dose of the study product than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose and recommended dose of the study product is found.
PROBLEM TO BE SOLVED: To obtain a new compound having a cyclooxygenase-2-inhibiting activity, etc., and useful as a medicine such as an antiinflammatory agent, etc. SOLUTION: This new compound is represented by formula I (R1 is H, a 1-7C alkyl, a 2-7C alkenyl, an aryl, etc.; R2 is SO2 -R5 ; R5 is a 1-3C alkyl; R3 is an aryl, a 3-6C cycloalkyl, etc.), e.g. 2-ethyl-1-(4-fluorobenzoyl)-5 methanesulfonylindole. The compound of formula I is obtained by reacting a compound of formula II with a carboxylic acid of the formula: R3 COOH or its reactive derivative in the presence of a base (e.g. sodium hydride) in a protonic solvent (e.g. dimethylformamide) at 0-100 deg.C. The compound of formula I can be administered by an oral administration method or by a parenteral administration method such as an intravenous injection method, an application method to mucosa or a percutaneous administration method at a daily dose of 3-150mg/kg by the oral administration method or at a daily dose of 1-50mg/kg by the parenteral administration method.
We developed a multimodal ultrasound (US) deep learning (DL) fusion model to automatically classify early fibrosis in patients with chronic kidney disease (CKD). This prospective study included patients with CKD who underwent continuous gray-scale US, superb microvascular imaging, and strain elastography from May to November 2022. According to the pathological tubular atrophy and interstitial fibrosis score, patients were divided into minimal and mild groups (affected area ≤10% and 11 - 25% of the total cortical volume, respectively). The dataset was divided into training (70%) and test (30%) sets. A DL model combining the features of the three US modes was developed to predict early fibrosis in patients with CKD. We compared these findings with the area under the receiver operating characteristic curve (AUC) of the clinical model by analyzing the receiver operating characteristic curve in the test set. The AUC of single-mode DL based on gray-scale US, superb microvascular imaging, and strain elastography was 0.682, 0.745, and 0.648, respectively, while that of the multimodal US DL model was 0.86. The accuracy, specificity, and sensitivity of the multimodal US DL model were 0.779, 0.767, and 0.796, respectively, and the negative and positive predictive values were 0.842 and 0.706, respectively. The AUC of the multimodal US DL model was significantly better than that of the single-mode DL and clinical models. The DL algorithm developed using multimodal US images can effectively predict early fibrosis in patients with CKD with significantly greater accuracy than single-mode DL or clinical models.
BACKGROUND AND AIMS: Inherited short telomeres are associated with a risk of liver disease, whereas longer telomeres predispose to cancer. The association between telomere length and risk of HCC and cholangiocarcinoma remains unknown.
APPROACH AND RESULTS: We measured leukocyte telomere length using multiplex PCR in 63,272 individuals from the Danish general population. Telomere length and plasma ALT concentration were not associated (β = 4 ×10 -6 , p -value = 0.06) in a linear regression model, without any signs of a nonlinear relationship. We tested the association between telomere length and risk of cirrhosis, HCC, and cholangiocarcinoma using Cox regression. During a median follow-up of 11 years, 241, 76, and 112 individuals developed cirrhosis, HCC, and cholangiocarcinoma, respectively. Telomere length and risk of cirrhosis were inversely and linearly associated ( p -value = 0.004, p for nonlinearity = 0.27). Individuals with telomeres in the shortest vs. longest quartile had a 2.25-fold higher risk of cirrhosis. Telomere length and risk of HCC were nonlinearly associated ( p -value = 0.009, p -value for nonlinearity = 0.01). This relationship resembled an inverted J-shape, with the highest risk observed in individuals with short telomeres. Individuals with telomeres in the shortest versus longest quartile had a 2.29-fold higher risk of HCC. Telomere length was inversely and linearly associated with the risk of cholangiocarcinoma. Individuals with telomeres in the shortest versus longest quartile had a 1.86-fold higher risk of cholangiocarcinoma.
CONCLUSIONS: Shorter telomere length is associated with a higher risk of cirrhosis, HCC, and cholangiocarcinoma.
A portable device for storing and providing access to a user's medical and demographic information. The portable storage device allow a medical provider immediate access to the user's current medical, demographic, and insurance information without the need to ask questions or fill out written forms. A system and method of using the portable storage device includes a customer portal hosted on a remote server that is accessible to the user. The user can create and update their electronic user record on the portal as needed. The medical provider can access the electronic user record via an external device interface at the point of service. The external device interface may communicate with a local electronic medical record system and may update the electronic user record on the portable storage device following an appointment.
Patients randomized to this arm will receive intravenous isotonic (0.9%) saline. The rate of isotonic saline will be 3 mL/kg give in the one hour before CT and 1 mL/kg/hour for 6 hours post-CT as per Canadian guidelines. Patients weighing more than 110 kg will receive the rate as per a 110 kg patient. The dose will be rounded up to the nearest 5 mL.
This study will allow researchers to assess the potency of investigational LRRK2 inhibitors, outside of participant bodies. It will enroll Parkinson's disease patients (LRRK2 G2019S symptomatic carriers and idiopathic) and healthy volunteers meeting eligibility criteria. The study will consist of a maximum of two study visits, a selection visit to check eligibility criteria, and a sample collection visit. The two visits can take place on the same day or can occur within 14 days of each other. Participants will be assigned to Cohort A or Cohort B, each include a blood sample collection, and an optional cerebrospinal fluid (CSF) collection in Cohort A. No investigational product, study drug, will be administered to study participants.
The invention provides new methods of treatment using TGF-β3 to inhibit scarring in humans, and TGF-β3 for new uses in the inhibition of scarring in humans. In a first incidence of treatment each centimetre of wound margin, or each centimetre of a site at which a wound is to be formed, is provided with between approximately 350ng and 1000ng of TGF-β3; and in a second incidence of treatment, occurring after a wound is formed, and between 8 and 48 hours after the first incidence of treatment, the wound is provided with an amount of between approximately 350ng and 1000ng of TGF-β3 per centimetre of wound margin in which scarring is to be inhibited. The amount of TGF-β3 provided may be the same in each incidence of treatment. The amount of TGF-β3 provided per centimetre in each incidence of treatment may preferably be approximately 500ng. The TGF-β3 may be provided by intradermal injection. Also provided are kits and methods of selecting an appropriate treatment regime for inhibiting scarring associated with the healing of a human wound.
This pilot randomized control trial will be testing an empowerment-based virtual group diabetes self-management education and support (DSME/S) for African American/Black adults with type 2 diabetes living in Detroit. Participants interested in participating in this study will first be consented then they will complete a baseline health assessment including a questionnaire and physiologic testing. Using a 50/50 randomization scheme, participants will be randomized to either a control group or the virtual DSME/S group and be told of their placement. Participants randomized to the control group will receive community resources, diabetes specific newsletters, and pedometers. Participants randomized to the virtual DSME/S group will receive 10-weekly 1-hour virtual DSME/S sessions with a certified diabetes care and education specialists through Zoom for Health at the University of Michigan, a HIPPA compliant platform. After the intervention is complete and then again 3 months later, participants in both groups will be invited to complete an additional health assessment.

However, due to low recruitment we removed the control arm and offered all participants virtual DSME/S.
Persistent epithelial defects (PED) are corneal lesions that do not heal within the first two weeks of conventional treatment (i.e. preservative-free lubricant, bandage contact lens (BCL), ocular lubricant ointment, eye patching). These defects are the result of the loss of certain lacrimal factors that maintain the integrity and homeostasis of the corneal epithelium and ocular surface. Normally, PED heal rapidly in the healthy eye. However, underlying ocular surface pathology can slow down the healing process and contribute to the persistence of the epithelial defect. Hematopoietic derivatives such as autologous platelet-rich plasma (PRP) may replace these missing components and eventually lead to complete healing in a faster and more comfortable way for the patient. The objective of this study is to determine if PRP combined with BCL is more effective than preservative-free lubricant combined with BCL or than eye patch with ocular lubricant ointment for the treatment of PED. Participants will be randomly assigned to one of the three groups and treatment will be administered until achieving complete defect closure. The effectiveness of each treatment will be measured in terms of days taken to achieve complete closure. Since PED is a complex disease that is difficult to treat, the available treatments are not very effective, therefore, PED might progress even to perforation regardless of the treatment. In this last scenario, we will provide appropriate treatment for progressive corneal thinning and corneal perforation
Experimental group subjects were required to attend 2 supervised exercise sessions and 2 counseling sessions during Week 1 and Week 2. Supervised exercise and counseling sessions are realized successively. For Week 3 to 8, participants were required to attend 1 supervised exercise session and 1 counseling session plus 1 home exercise session.